Serum lipid changes after estrogen therapy in prostatic carcinoma.
A study of serum lipid fraction changes in 15 estrogen-treated patients with carcinoma of the prostate is conducted. Estrogen therapy is known to be associated with cardiovascular complications. certain serum lipid fraction changes, particularly elevated low-density lipoprotein (LDL) and decreased high-density lipoprotein (HDL), are known to increase the risk of cardiovascular diseases. In our study, decrease in total cholesterol, increase in triglycerides, decreased LDL, and LDL/HDL ratio in combination with elevated HDL fraction suggest that the lipid changes are not the mediators of above complications.
D000368:Aged; D001161:Arteriosclerosis / Q000209:etiology; D002277:Carcinoma / Q000097:blood / Q000188:drug therapy*; D002784:Cholesterol / Q000097:blood; D004054:Diethylstilbestrol / Q000627:therapeutic use*; D006801:Humans; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D012306:Risk; D014280:Triglycerides / Q000097:blood
D008055:Lipids; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D014280:Triglycerides; D004054:Diethylstilbestrol; D002784:Cholesterol